|
Small Molecule Inhibitors Targeting OTUD4-CD73 Interaction for Immune-Cold Tumors
Application
This technology introduces small molecule inhibitors, ST80 and Z22, to disrupt the protein-protein interaction (PPI) between OTUD4 and CD73. These inhibitors enhance tumor immunogenicity by reducing CD73 stabilization, improving the immune response in triple-negative breast cancer (TNBC) and other immune-cold tumors.
Key Benefits
ST80...
Published: 12/9/2025
Contributor(s): Yong Wan, Yueming Zhu, Ivet Bahar, Anupam Banerjee, Jiyoung Lee
|
|
Protein Polymers for Organelle Engineering
Application
Protein polymers enabling engineering of human membraneless organelles.
Key Benefits
Versatile applications across immunotherapy, cell therapy, and other therapeutic modalities.
High biocompatibility with minimal reactivity with endogenous molecules.
Deployable for organelle-level functionalization of human cells.
Market Summary
Proteins...
Published: 12/5/2025
Contributor(s): Felipe Quiroz, Ian Sicher, Spencer Hayes, Maria Giraldo-Castaño, Mariell Pascual, Alexa Avecilla
|
|
Multifunctional Drug and Immune Modulator Delivery Nanoparticles for the Treatment of Cancer Patients with Comorbid Atherosclerosis
Application
A multifunctional immuno-therapy nanoparticle (PD1Y-HANP/Avasimbe) that has ability of targeting and inhibiting immune checkpoint PDL-1 while producing therapeutic effects on tumors and atherosclerosis.
Key Benefits
Multifunctional immunotherapy for cancer patients with atherosclerosis.
Shown to inhibit tumor growth and prevention...
Published: 9/3/2025
Contributor(s): Lily Yang, Lei Zhu
|
